Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HEPA 
Hepion Pharmaceuticals Inc (HEPA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: HEPA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.94M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 1 | Beta 1.52 | 52 Weeks Range 0.03 - 44.50 | Updated Date 08/28/2025 |
52 Weeks Range 0.03 - 44.50 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -45.85 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate - | Actual -0.09 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -98.47% | Return on Equity (TTM) -368.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -154027 | Price to Sales(TTM) - |
Enterprise Value -154027 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.1 | Shares Outstanding 10976300 | Shares Floating 11620317 |
Shares Outstanding 10976300 | Shares Floating 11620317 | ||
Percent Insiders - | Percent Institutions 0.2 |
Upturn AI SWOT
Hepion Pharmaceuticals Inc
Company Overview
History and Background
Hepion Pharmaceuticals Inc. was founded in 2015. It is a clinical-stage biopharmaceutical company focused on developing therapies for liver diseases.
Core Business Areas
- Drug Development: Focuses on the discovery and development of novel therapeutic candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases.
Leadership and Structure
Robert Foster is the current CEO. The company has a typical biotech structure with research, clinical development, and corporate functions.
Top Products and Market Share
Key Offerings
- Rencofilstat: Rencofilstat is Hepion's lead drug candidate, an oral cyclophilin inhibitor targeting NASH. It is currently in clinical trials. Market share data is not yet available as it is not yet approved. Competitors include Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX).
Market Dynamics
Industry Overview
The liver disease therapeutics market, especially for NASH, is a large and growing market with significant unmet medical need. Multiple companies are developing therapies, creating a competitive landscape.
Positioning
Hepion is a smaller player in the NASH space, focused on its unique cyclophilin inhibition mechanism. Its competitive advantage relies on the efficacy and safety profile demonstrated in clinical trials.
Total Addressable Market (TAM)
The NASH market is projected to reach tens of billions of dollars. Hepion is positioning itself to capture a significant share of this market if Rencofilstat is approved.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (cyclophilin inhibition)
- Focus on NASH, a large and unmet market
- Experienced management team
Weaknesses
- Limited financial resources compared to larger competitors
- Single lead drug candidate (Rencofilstat)
- NASH drug development is high risk
Opportunities
- Positive clinical trial results for Rencofilstat
- Partnerships with larger pharmaceutical companies
- Expansion into other liver disease indications
Threats
- Failure of Rencofilstat in clinical trials
- Competition from other NASH therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- GILD
Competitive Landscape
Hepion faces competition from larger, more established pharmaceutical companies with greater resources. It relies on the differentiation of Rencofilstat to compete.
Growth Trajectory and Initiatives
Historical Growth: Hepion's growth is measured by the advancement of Rencofilstat through clinical trials.
Future Projections: Future growth depends on positive clinical trial data and potential regulatory approval. Analyst projections are highly speculative at this stage.
Recent Initiatives: Recent initiatives focus on enrolling patients in ongoing clinical trials and preparing for potential regulatory submissions.
Summary
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on developing therapies for liver diseases, particularly NASH. The company's success hinges on the clinical trial results of its lead drug candidate, Rencofilstat. While the NASH market presents a significant opportunity, Hepion faces competition from larger players and the inherent risks of drug development. Securing partnerships and demonstrating strong clinical data will be crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hepion Pharmaceuticals Inc. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Please consult with a qualified financial advisor before making any investment decisions. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hepion Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Morristown, NJ, United States | ||
IPO Launch date 2014-02-11 | Interim CEO & Director Dr. Kaouthar Lbiati M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://hepionpharma.com |
Full time employees - | Website https://hepionpharma.com | ||
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.